|
Thursday, March 27, 2008
|
|
|
|
|
|
|
11:00-13:00
|
Registration
|
|
|
|
|
|
|
13:00-13:10
|
Introduction
|
|
|
13:00-13:10
|
Welcome
|
Bengt Winblad, Howard Fillit
|
|
|
|
|
|
13:10-15:00
|
The Economics of Dementia
|
Moderator: Bengt Winblad
|
|
13:10-13:25
|
The worldwide
costs of dementia: an overview
|
Anders Wimo
|
|
13.25-13.40
|
Prevalence – controversies,
impact on costs
|
Martin Prince
|
|
13:40-14:00
|
Excess
costs in dementia care and impact of comorbidities
– a North American perspective.
|
Howard Fillit
|
|
14:00-14:20
|
Excess costs in dementia care
– a European perspective.
|
Jean Georges
|
|
14:20-14:40
|
Behavioural disorders as cost
driver
|
Dan Murman
|
|
14:40-15:00
|
Panel discussion: methodological
issues, what's needed
|
PANEL: Eliot Schwam,
speakers
|
|
|
|
|
|
15:00-15:30
|
Break
|
|
|
|
|
|
|
15:30-17:30
|
A worldwide regulatory and payer
perspective
|
Moderator: Howard Fillit
|
|
15:30-15:50
|
The European
perspective: who pays and who cares in the EU?
|
Nina Bjelojrlic-Laakso
|
|
16:00-16:20
|
The
American perspective: Medicare and Medicaid
|
Richard Stefanacci
|
|
16:20-16:40
|
The Asian
perspective
|
Guk-Hee
Suh
|
|
16:40-17:00
|
The
Latin American perspective
|
Raoul Arizaga
|
|
17:00-17:30
|
Panel discussion: at what price
will drugs be reimbursed? At what price will they be used?
|
PANEL: Howard Fillit, speakers
|
|
|
|
|
|
17:30
|
Reception, Hilton
Newark Airport
|
|
|
|
|
|
|
Friday, March 28
|
|
|
|
|
|
|
08:30-10:00
|
Pharmacoeconomics
of AD: Studies to date and methodological issues
|
Moderator: Serge Gauthier
|
|
08:30-09:00
|
Review of pharmacoeconomic data from previous clinical trials
|
Serge Gauthier
|
|
09:00-09:20
|
Measuring resource use: RUD Lite and other instruments
|
Anders Wimo
|
|
09:20-09:40
|
How can we improve the
incorporation of pharmacoeconomic data in
clinical efficacy studies?
|
Roy Jones
|
|
09:40-10:00
|
Effectiveness
studies and naturalistic designs
|
Lon Schneider
|
|
|
|
|
|
10:00-10:30
|
Coffee break
|
|
|
|
|
|
|
10:30 – 12:00
|
Screening, diagnostics,
imaging and biomarkers
|
Moderator: Lars-Olov Wahlund
|
|
10:30-10:50
|
Dementia diagnostics: current
status and future developments (incl. screening)
|
Lars-Olov Wahlund
|
|
10:50-11:10
|
Cost-effectiveness
of diagnostics and biomarkers
|
Linus Jönsson
|
|
11:10-11:30
|
In search of biochemical markers of AD
|
Holly Soares
|
|
11:30-12:00
|
Invited industry presentation
|
Juliana Setvawan
|
|
|
|
|
|
12:00-13:00
|
Lunch
|
|
|
|
|
|
|
13:00-14:30
|
Outcomes
|
Moderator: Richard Mohs
|
|
13:00-13:15
|
Measuring quality
of life in dementia
|
Jason Karlawich
|
|
13:15-13:30
|
Disease
quality registries and health economics
|
Kalle Spångberg
|
|
13:30-13:45
|
Individual goals as outcome
measure
|
Ken Rockwood
|
|
13:45-14:00
|
Maximum Acceptable Risk
and Healthy Year Equivalents in AD
|
Reed Johnson
|
|
14:00-14:30
|
Panel discussion: what is a
relevant outcome measure in AD?
|
PANEL: Richard Mohs and speakers
|
|
|
|
|
|
15:00-15:30
|
Break
|
|
|
|
|
|
|
15:30-17:30
|
Modelling / disease-modifying HE
models
|
Moderator: Linus Jönsson
|
|
15:30-16:00
|
Review
of model studies to date
|
Josh Cohen
|
|
16:00-16:20
|
Demonstation of disease modification in AD
|
Susanne Hendrix
|
|
16:20-16:40
|
A microsimulation framework for modeling Alzheimer's
disease
|
Anders Gustavsson
|
|
16:40-17:00
|
Modeling AD progression - industry perspective
|
Trent McLaughlin
|
|
17:00-17:30
|
Panel discussion: the future of
modelling
|
PANEL: Ray Townsend, speakers
|
|
|
|
|
|
~19:00
|
Dinner at Restaurant Assaggini Di
Roma, Newark, NJ
|
|
|
|
|
|
|
Saturday March 29
|
|
|
|
|
|
|
09:00-10:40
|
Brainstorming: improving design
of cost-effectiveness studies in AD
|
Moderator: Albrecht Stöffler
|
|
09:00-09:25
|
What is the ideal
design for a clinical cost effectiveness trial: a theoretical perspective
|
Ray Townsend
|
|
09:20-09:50
|
Caregiver outcomes
|
Krista
Lanctôt
|
|
09:50-10:25
|
How do disease modifying studies
differ from symptomatic studies?
|
Howard Feldman
|
|
10:15-10:40
|
Designing clinical cost
effectiveness trials in Alzheimer’s disease; a brainstorming session
|
PANEL: speakers
|
|
10:40-11:00
|
Concluding remarks
|
Anders Wimo, Linus Jönsson
|
